Conditions: Diabetes Mellitus, Type 2
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 41
Healthy volunteers: no

Brief summary:
The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of African American origin.

Detailed description:

Arms:
arm 1: Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation

Interventions: intervention 1: linagliptin QD (once daily) for 7 days
Intervention descriptions: intervention 1: dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration

Protocol document: